Myeloma Novel Drug Targets and agents
Mezigdomide (MEZI) reverses T-cell exhaustion (Tex) through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways
Nathan Martin, PhD (he/him/his)
Director - Translational Research
Bristol Myers Squibb, United States